The Importance of the Results of the Phase 3 Trial Assessing Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19

Name: The Importance of the Results of the Phase 3 Trial Assessing Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
Uploaded: 2021-07-06T18:00:00.000Z
Description: Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

July 6, 2021

Video

Conference|ADA Scientific Sessions - American Diabetes Association Scientific Sessions

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod explained why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.